title: Development and Validation of the Eyelash Satisfaction Questionnaire.
abstract: BACKGROUND
  Patient-reported outcome (PRO) measures have been used to assess treatment benefit in a variety of therapeutic areas and are now becoming increasingly important in aesthetic research.
  
  
  OBJECTIVE
  The objective of the current study was to develop and validate a new PRO measure (Eyelash Satisfaction Questionnaire [ESQ]) to assess satisfaction with eyelash prominence.
  
  
  METHODS
  The content of the questionnaire (including conceptual framework and questionnaire items) was generated by review of literature, participant interviews, and expert opinion. Cognitive interviews were conducted to pilot test the questionnaire. Psychometric properties of the questionnaire were examined in a combined sample of participants (n = 970) completing Internet- (n = 909) and paper-based (n = 61) versions. Item- and domain-level properties were examined using modern and classical psychometrics.
  
  
  RESULTS
  Content-based analysis of qualitative data demonstrated the presence of 3 distinct domains (Length, Fullness, Overall Satisfaction; Confidence, Attractiveness, and Professionalism; and Daily Routine). Initial confirmatory factor analysis (CFA) results of 23 items revealed insufficient model-data fit (comparative fit index [CFI] of 0.86 and a non-normed fit index [NNFI] of 0.82). A revised model using 9 items (3 per domain) achieved appropriate fit (CFI of 0.99 and NNFI of 0.97). Analyses revealed measurement equivalence across the Internet- and paper-based versions. The 3 ESQ domains had strong internal consistency reliability (Cronbach's α [range] = 0.919-0.976) and adequate convergent and discriminant validity.
  
  
  CONCLUSIONS
  The ESQ was found to be a reliable and valid PRO measure for assessing satisfaction with eyelash prominence. LEVEL OF EVIDENCE 3: Therapeutic.
authors.affiliation: At the time of this research, Dr Dang was President and Senior Research Scientist at Consulting Measurement Group, Torrance, California. Dr Cole was Director and Senior Scientist and Dr Yang was Senior Scientist at QualityMetric, Inc., Lincoln, Rhode Island. Dr Burgess was Director of Global Health Outcomes Strategy and Research, Dr Daniels was Manager of Global Health Outcomes Strategy and Research, and Mr Walt was Director of Global Strategic Marketing at Allergan, Inc., Irvine, California.
authors.forename: Jeff
authors.initials: J
authors.lastname: Dang
authors.affiliation: At the time of this research, Dr Dang was President and Senior Research Scientist at Consulting Measurement Group, Torrance, California. Dr Cole was Director and Senior Scientist and Dr Yang was Senior Scientist at QualityMetric, Inc., Lincoln, Rhode Island. Dr Burgess was Director of Global Health Outcomes Strategy and Research, Dr Daniels was Manager of Global Health Outcomes Strategy and Research, and Mr Walt was Director of Global Strategic Marketing at Allergan, Inc., Irvine, California.
authors.forename: Jason C
authors.initials: JC
authors.lastname: Cole
authors.affiliation: At the time of this research, Dr Dang was President and Senior Research Scientist at Consulting Measurement Group, Torrance, California. Dr Cole was Director and Senior Scientist and Dr Yang was Senior Scientist at QualityMetric, Inc., Lincoln, Rhode Island. Dr Burgess was Director of Global Health Outcomes Strategy and Research, Dr Daniels was Manager of Global Health Outcomes Strategy and Research, and Mr Walt was Director of Global Strategic Marketing at Allergan, Inc., Irvine, California.
authors.forename: Somali M
authors.initials: SM
authors.lastname: Burgess
authors.affiliation: At the time of this research, Dr Dang was President and Senior Research Scientist at Consulting Measurement Group, Torrance, California. Dr Cole was Director and Senior Scientist and Dr Yang was Senior Scientist at QualityMetric, Inc., Lincoln, Rhode Island. Dr Burgess was Director of Global Health Outcomes Strategy and Research, Dr Daniels was Manager of Global Health Outcomes Strategy and Research, and Mr Walt was Director of Global Strategic Marketing at Allergan, Inc., Irvine, California.
authors.forename: Min
authors.initials: M
authors.lastname: Yang
authors.affiliation: At the time of this research, Dr Dang was President and Senior Research Scientist at Consulting Measurement Group, Torrance, California. Dr Cole was Director and Senior Scientist and Dr Yang was Senior Scientist at QualityMetric, Inc., Lincoln, Rhode Island. Dr Burgess was Director of Global Health Outcomes Strategy and Research, Dr Daniels was Manager of Global Health Outcomes Strategy and Research, and Mr Walt was Director of Global Strategic Marketing at Allergan, Inc., Irvine, California.
authors.forename: Selena R
authors.initials: SR
authors.lastname: Daniels
authors.affiliation: At the time of this research, Dr Dang was President and Senior Research Scientist at Consulting Measurement Group, Torrance, California. Dr Cole was Director and Senior Scientist and Dr Yang was Senior Scientist at QualityMetric, Inc., Lincoln, Rhode Island. Dr Burgess was Director of Global Health Outcomes Strategy and Research, Dr Daniels was Manager of Global Health Outcomes Strategy and Research, and Mr Walt was Director of Global Strategic Marketing at Allergan, Inc., Irvine, California.
authors.forename: John G
authors.initials: JG
authors.lastname: Walt
mesh_terms: D000328:Adult; D000368:Aged; D000069580:Bimatoprost / Q000627:therapeutic use*; D002140:California; D002641:Chicago; D003071:Cognition; D032882:Comprehension; D004954:Esthetics; D005140:Eyelashes / Q000187:drug effects* / Q000254:growth & development; D005260:Female; D017144:Focus Groups; D006801:Humans; D007039:Hypotrichosis / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D011594:Psychometrics; D015203:Reproducibility of Results; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000069580:Bimatoprost